Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - PubMed

UK Vaccine Task Force and National Institute for Health Research.
www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov